Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Menalled, Liliana B ^a   Patry, Monica ^a   Ragland, Natalie ^a   Lowden, Phillip A S ^b   Goodman, Jennifer ^a   Minnich, Jennie ^a   Zahasky, Benjamin ^a   Park, Larry ^c   Leeds, Janet ^c   Howland, David ^c   Signer, Ethan ^c   Tobin, Allan J ^c   Brunner, Daniela ^a,d  

^a PSYCHOGENICS INC   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DRUG DERIVATIVE; MINOCYCLINE; UBIDECARENONE; UBIQUINONE;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; BODY WEIGHT; C57BL MOUSE; DBA MOUSE; DISEASE MODEL; DRUG EFFECT; FEMALE; GENETICS; HAND STRENGTH; HUNTINGTON CHOREA; MALE; MOTOR PERFORMANCE; MOUSE;

ANIMALS; ANTI-BACTERIAL AGENTS; BEHAVIOR, ANIMAL; BODY WEIGHT; DISEASE MODELS, ANIMAL; FEMALE; HAND STRENGTH; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MINOCYCLINE; MOTOR SKILLS; UBIQUINONE;

EID: 78149474887     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009793     Document Type: Article

References (79)

1. The_Huntington's_Disease_Collaborative_Research_Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
2. Group THsDCR (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
3. Li S, Li XJ (2006) Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener 1: 19.
4. Hersch SM, Ferrante RJ (2004) Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx 1: 298-306.
5. Wagner LA, Menalled L, Gomeniouk A, Brunner D, Leavitt BR (2008) Huntington Disease. In: Borsini RMaF, ed. Animal and Translational Models of Behavioral Disorders Elsevier.
6. Huntington Study Group (2006) Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology 66: 366-372.
7. Bonelli RM, Hofmann P (2007) A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother 8: 141-153.
8. Beal MF (2004) Therapeutic effects of coenzyme Q10 in neurodegenerative diseases. Methods Enzymol 382: 473-487.
9. Bhagavan HN, Chopra RK (2006) Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 40: 445-453.
10. Kamzalov S, Sumien N, Forster MJ, Sohal RS (2003) Coenzyme Q intake elevates the mitochondrial and tissue levels of Coenzyme Q and alphatocopherol in young mice. J Nutr 133: 3175-3180.
11. Matthews RT, Yang L, Browne S, Baik M, Beal MF (1998) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A 95: 8892-8897.
12. Shults CW, Flint Beal M, Song D, Fontaine D (2004) Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 188: 491-494.
13. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, et al. (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22: 1592-1599.
14. Smith KM, Matson S, Matson WR, Cormier K, Del Signore SJ, et al. (2006) Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta 1762: 616-626.
15. Stack EC, Smith KM, Ryu H, Cormier K, Chen M, et al. (2006) Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta 1762: 373-380.
16. Schilling G, Coonfield ML, Ross CA, Borchelt DR (2001) Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett 315: 149-153.
17. Schilling G, Savonenko AV, Coonfield ML, Morton JL, Vorovich E, et al. (2004) Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol 187: 137-149.
18. Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, et al. (2009) Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 109: 1427-1439.
19. Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, et al. (2008) Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem 104: 1613-1621.
20. Aronson AL (1980) Pharmacotherapeutics of the newer tetracyclines. J Am Vet Med Assoc 176: 1061-1068.
21. Bantubungi K, Jacquard C, Greco A, Pintor A, Chtarto A, et al. (2005) Minocycline in phenotypic models of Huntington's disease. Neurobiol Dis 18: 206-217.
22. Lin S, Wei X, Xu Y, Yan C, Dodel R, et al. (2003) Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sciences 72: 1635-1641.
23. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J (2001) Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia. J Neurosci 21: 2580-2588.
24. Stirling D, Koochesfahani K, Steeves J, Tetzlaff W (2005) Minocycline as a Neuroprotective Agent. The Neuroscientist 11: 308.
25. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, et al. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6: 797-801.
26. Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, et al. (2003) Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 54: 186-196.
27. Mievis S, Levivier M, Communi D, Vassart G, Brotchi J, et al. (2007) Lack of Minocycline Efficiency in Genetic Models of Huntington's Disease. NeuroMolecular Medicine 9: 47-54.
28. Diguet E, Fernagut P, Wei X, Du Y, Rouland R, et al. (2004) Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. European Journal of Neuroscience 19: 3266-3276.
29. Menalled L, El-Khodor BF, Patry M, Suarez-Farinas M, Orenstein SJ, et al. (2009) Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis.
30. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506.
31. Morton AJ, Lagan MA, Skepper JN, Dunnett SB (2000) Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. J Neurocytol 29: 679-702.
32. Axisa B, Naylor AR, Bell PR, Thompson MM (2000) Simple and reliable method of doxycycline determination in human plasma and biological tissues. J Chromatogr B Biomed Sci Appl 744: 359-365.
33. Axisa B, Naylor A, Bell P, Thompson M (2000) Simple and reliable method of doxycycline determination in human plasma and biological tissues. Journal of Chromatography B: Biomedical Sciences and Applications 744: 359-365.
34. Singer J (1998) Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. Journal of Educational and Behavioral Statistics 23: 323.
35. Kuha J (2004) AIC and BIC: Comparisons of assumptions and performance. Sociological Methods & Research 33: 188.
36. Lüesse H-G, Schiefer J, Spruenken A, Puls C, Block F, et al. (2001) Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Behavioural Brain Research 126: 185-195.
37. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, et al. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19: 3248-3257.
38. Andes D, Craig WA (2002) Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19: 261-268.
39. Lonnrot K, Holm P, Lagerstedt A, Huhtala H, Alho H (1998) The effects of lifelong ubiquinone Q10 supplementation on the Q9 and Q10 tissue concentrations and life span of male rats and mice. Biochem Mol Biol Int 44: 727-737.
40. Ibrahim WH, Bhagavan HN, Chopra RK, Chow CK (2000) Dietary Coenzyme Q10 and Vitamin E Alter the Status of These Compounds in Rat Tissues and Mitochondria. J Nutr 130: 2343-2348.
41. Dallner G, Sindelar P (2000) Regulation of ubiquinone metabolism. Free Radical Biology and Medicine 29: 285-294.
42. Morales L, Estevez J, Suarez H, Villalobos R, Chacin de Bonilla L, et al. (1989) Nutritional evaluation of Huntington disease patients. Am J Clin Nutr 50: 145-150.
43. Petersen A, Bjorkqvist M (2006) Hypothalamic-endocrine aspects in Huntington's disease. European Journal of Neuroscience 24: 961-967.
44. Nithianantharajah J, Hannan AJ (2006) Enriched environments, experiencedependent plasticity and disorders of the nervous system. Nat Rev Neurosci 7: 697-709.
45. van Dellen A, Blakemore C, Deacon R, York D, Hannan AJ (2000) Delaying the onset of Huntington's in mice. Nature 404: 721-722.
46. Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, et al. (2002) Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 51: 235-242.
47. Spires TL, Grote HE, Varshney NK, Cordery PM, van Dellen A, et al. (2004) Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci 24: 2270-2276.
48. Lazic SE, Grote HE, Blakemore C, Hannan AJ, van Dellen A, et al. (2006) Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur J Neurosci 23: 1829-1838.
49. Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, et al. (2005) Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65: 1834-1836.
50. Huntington Study Group (2001) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57: 397-404.
51. Hersch S, Fink K, Vonsattel JP, Friedlander RM (2003) Minocycline is protective in a mouse model of Huntington's disease. Ann Neurol 54: 841; author reply 842-843.
52. Pallier P, Drew C, Morton A (2008) The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are taskand protocol-dependent: Influence of non-motor factors on locomotor function. Brain Research Bulletin.
53. Yang L, Sugama S, Chirichigno J, Gregorio J, Lorenzl S, et al. (2003) Minocycline enhances MPTP toxicity to dopaminergic neurons. Journal of Neuroscience Research 74: 278-285.
54. Tsuji M, Wilson MA, Lange MS, Johnston MV (2004) Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Experimental Neurology 189: 58-65.
55. Guerin C, Laterra J, Masnyk T, Golub L, Brem H (1992) Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. Biochem Biophys Res Commun 188: 740-745.
56. Attur M, Patel R, Patel P, Abramson S, Amin A (1999) Tetracycline Up-Regulates COX-2 Expression and Prostaglandin E2 Production Independent of Its Effect on Nitric Oxide. The Journal of Immunology 162: 3160-3167.
57. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan P, et al. (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window National Acad Sciences. pp 13496-13500.
58. Goulden V, Glass D, Cunliffe WJ (1996) Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 134: 693-695.
59. Shapiro LE, Knowles SR, Shear NH (1997) Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 133: 1224-1230.
60. Good ML, Hussey DL (2003) Minocycline: stain devil? Br J Dermatol 149: 237-239.
61. Donnet A, Dufour H, Graziani N, Grisoli F (1992) Minocycline and benign intracranial hypertension. Biomed Pharmacother 46: 171-172.
62. Lawson TM, Amos N, Bulgen D, Williams BD (2001) Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 40: 329-335.
63. Schlienger RG, Bircher AJ, Meier CR (2000) Minocycline-induced lupus. A systematic review. Dermatology 200: 223-231.
64. Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM (1998) Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med 152: 1132-1136.
65. Settgast AM, Groth T, Gertner E (2003) Minocycline-induced central nervous system-pulmonary hypersensitivity syndrome. Int J Dermatol 42: 316-317.
66. Seaman HE, Lawrenson RA, Williams TJ, MacRae KD, Farmer RD (2001) The risk of liver damage associated with minocycline: a comparative study. J Clin Pharmacol 41: 852-860.
67. Lawrenson RA, Seaman HE, Sundstrom A, Williams TJ, Farmer RD (2000) Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf 23: 333-349.
68. Gordon P, Moore D, Gelinas D, Qualls C, Meister M, et al. (2004) Placebocontrolled phase I/II studies of minocycline in amyotrophic lateral sclerosis AAN Enterprises. pp 1845-1847.
69. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, et al. (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6: 1045-1053.
70. Bonelli RM, Hodl AK, Hofmann P, Kapfhammer HP (2004) Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 19: 337-342.
71. Bonelli RM, Heuberger C, Reisecker F (2003) Minocycline for Huntington's disease: an open label study. Neurology 60: 883-884.
72. Thomas M, Ashizawa T, Jankovic J (2004) Minocycline in Huntington's disease: a pilot study. Mov Disord 19: 692-695.
73. Dragatsis I, Goldowitz D, Del Mar N, Deng Y, Meade CL, L, et al. (2009) CAG repeat lengths >_335 attenuate the phenotype in the R6/2 Huntington's Disease mouse. Neurobiology of Disease.
74. Morton AJ, Glynn D, Leavens W, Zheng Z, Faull RL, et al. (2009) Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol Dis 33: 331-341.
75. van der Burg JM, Bacos K, Wood NI, Lindqvist A, Wierup N, et al. (2008) Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 29: 41-51.
76. Benatar M (2007) Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 26: 1-13.
77. Ioannidis JP (2006) Evolution and translation of research findings: from bench to where? PLoS Clin Trials 1: e36.
78. Diguet E, Gross C, Tison F, Bezard E (2004) Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. Experimental Neurology 189: 1-4.
79. Ioannidis JP (2007) Molecular evidence-based medicine: evolution and integration of information in the genomic era. Eur J Clin Invest 37: 340-349.